The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASH 2017 | Results of the TRANSCEND study of CAR T Cell Product JCAR017 in patients with R/R aggressive B-NHL

Name: Results of the TRANSCEND study of CAR T Cell Product JCAR017 in patients with R/R aggressive B-NHL
Uploaded: 2017-12-11T16:57:11.000Z
Duration: 6 min 24 s
Description: Dr Jeremy Abramson, MD, from the Massachusetts General Hospital, Boston, MA, gives us a detailed presentation of progress in the TRANSCEND-NHL-001 trial (NCT02631044) presented at the ASH 2017 meeting in Atlanta, GA. He covers the rationale, design, results and safety profile as well as giving us his opinion on the data.

Jeremy Abramson • 11 Dec 2017

ASH 2017

B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma CAR-T Lisocabtagene maraleucel

TRANSCEND-NHL-001

Dr Jeremy Abramson, MD, from the Massachusetts General Hospital, Boston, MA, gives us a detailed presentation of progress in the TRANSCEND-NHL-001 trial (NCT02631044) presented at the ASH 2017 meeting in Atlanta, GA. He covers the rationale, design, results and safety profile as well as giving us his opinion on the data.